Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 5, 2022

View Archived Issues

OR5B21 is associated with breast cancer metastasis

Activation of ATF4 is required for DLBCL growth

Amgen discloses new SCN9A blockers

MCUF-651, a GC-A PAM for the treatment of cardiovascular, renal and metabolic diseases

Incyte divulges new ACVR1 inhibitors

Novartis presents new Cav1.2 activators

Vertex Pharmaceuticals identifies new APOL1 inhibitors

Merck & Co. synthesizes RIPK1 inhibitors

Discovery of novel selective and orally bioavailable AR-V7 degrader

Biogen exercises option to license preclinical ASO for spinal muscular atrophy

Dusquetide effective at reducing tumor size in nonclinical xenograft models

Novel covalent BTK inhibitor with good potency and reduced CYP inhibitory activity

Grant supports Cognition's evaluation of sigma-2 receptor modulators for Parkinson's disease

P-Esbp-DOX prolongs survival in mouse model of aggressive liver metastasis of colorectal cancer

Study of HT-ALZ shows decrease in Abeta in Alzheimer's disease mouse model after acute treatment

Seed funding at Ray Therapeutics supports development of RAY-001 for retinitis pigmentosa

NaNotics and Mayo Clinic collaborate on NaNot targeting soluble PD-L1

Insilico Medicine nominates preclinical candidates for IBD and anemia of CKD

Study shows nanoparticles could help reduce acute lung inflammation in COVID-19

Ideaya acquires INQUIRE chemical library

Tonix and Kansas State enter option agreement and research collaboration on LNP-free mRNA vaccines

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 5, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 4, 2025.
First phase of synthetic human genome project successfully completes
BioWorld
The first phase of the U.K. synthetic human genome project has successfully completed, realizing key steps in chromosome synthesis. The work has demonstrated a...
Epigenetic technology could eliminate misfolded prion proteins
BioWorld Science
The number of deaths caused by prion diseases reaches about 30,000 annually. Only 5 months pass from the diagnosis of seemingly healthy patients to the fatal...
Laigo raises €11.5M seed money for targeted protein degradation
BioWorld Science
Laigo Bio BV has raised €11.5 million (US$13.7 million) in a seed round for the further development of a new approach to inducing targeted protein degradation by...